|Bid||43.00 x 800|
|Ask||48.60 x 3200|
|Day's Range||43.90 - 44.97|
|52 Week Range||27.23 - 50.44|
|Beta (3Y Monthly)||1.79|
|PE Ratio (TTM)||24.32|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.64|
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced new data from two studies of Vectra® that evaluated the test’s ability to track treatment response in patients with rheumatoid arthritis (RA). The studies were conducted by academic collaborators and will be presented at the American College of Rheumatology meeting in Chicago, IL. The key findings are that Vectra statistically significantly predicted response to tofacitinib and tracked response to rituximab.
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, announced today that Bendcare, a large professional organization empowering community rheumatologists in the United States, has endorsed Vectra® testing for adults with rheumatoid arthritis (RA). Bendcare focuses on the optimization of the patient journey and the specialty medical office through provider and patient education, product acquisition, and world-class products and data solutions, including a revolutionary prospective data analytics platform called Columbus.
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare professionals to identify patients with HER2-negative metastatic breast cancer (mBC) who have a germline BRCA mutation and are eligible for treatment with Pfizer’s PARP (poly ADP ribose polymerase) inhibitor, TALZENNA® (talazoparib). TALZENNA is indicated for the treatment of adult patients with deleterious or suspected deleterious germline (inherited) BRCA-mutated HER2-negative locally advanced or mBC. One in eight women are diagnosed with breast cancer in the United States, and one-third will progress to the metastatic stage of the disease.
Rising incidence of infectious diseases and increasing acceptance of companion diagnostics are driving the molecular diagnostics market.
NEW YORK, NY / ACCESSWIRE / October 11, 2018 / U.S. equities continued to tumble on Wednesday on rising yields and interest rates. Additionally, weakening tech stocks pressured the S&P 500 to its worst ...
Shares of Myriad Genetics Inc. soared 7% Wednesday in a down market, after it announced an agreement to carry out testing for Pfizer Inc. of a treatment for breast cancer. The Salt Lake City, Utah-based company said it will provide BRACAnalysis testing in a mid-stage trial of talazoparib, Pfizer's treatment for "triple negative breast cancer." Myriad specializes in testing hereditary cancers. Roughly 35,000 women are diagnozed with this type of cancer every year, according to Myriad, which said it has significantly lower survival rates and treatment options compared to other types of breast cancer. Myriad shares have gained 35% in 2018, while the S&P 500 has gained 7%.
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, announced today that it has signed a new laboratory services agreement with Pfizer Inc. Under the terms of the agreement, Myriad will provide BRACAnalysis CDx® testing in a Phase 2 study evaluating talazoparib, Pfizer’s investigational polymerase (PARP) inhibitor, for neo-adjuvant treatment of germline BRCA-mutated triple negative breast cancer.
NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced that it has signed a commercialization plan with Pfizer Inc. The plan is under an existing companion diagnostic agreement, in which Myriad is pursuing U.S. Food and Drug Administration (FDA) approval for its BRACAnalysis CDx® to be used as a companion diagnostic with Pfizer’s investigational PARP (poly ADP ribose polymerase) inhibitor, talazoparib. Talazoparib and BRACAnalysis CDx currently are under FDA review, with New Drug Application and Supplementary Premarket Approval submissions based on results from the EMBRACA trial, which evaluated talazoparib versus physician’s choice chemotherapy in patients with germline (inherited) BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. Myriad anticipates a regulatory decision from the FDA by December 2018.
SALT LAKE CITY, Sept. 26, 2018-- Myriad Genetics, Inc., a worldwide leader in personalized medicine, today announced that a health economic study to evaluate the financial impact of the GeneSight ® combinatorial ...
This was a retrospective study of individuals who had genetic testing from 2006-2016 at Myriad Genetics. Genetic variants were classified as Benign, Likely Benign, Variant of Uncertain Significance, Likely Pathogenic, or Pathogenic. The primary objective of this study was to measure the frequency and types of variant reclassification.
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
This article is intended for those of you who are at the beginning of your investing journey and want to start learning about core concepts of fundamental analysis on practicalRead More...
SALT LAKE CITY, Aug. 31, 2018-- Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the ...
Myriad Genetics Inc (NASDAQ:MYGN) files its latest 10-K with SEC for the fiscal year ended on June 30, 2018.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 22) Acer Therapeutics Inc (NASDAQ: ACER ) Avanos Medical Inc (NYSE: ...
The genetic testing leader announced fiscal fourth-quarter 2018 earnings results and gave guidance for next year. It's the news shareholders have been waiting for.
Shares of Target Corp. (TGT) jumped more than 5% after reporting second-quarter earnings per share of $1.47 on $17.55 billion in revenue, reflecting a 6.9% year-over-year increase. The company beat earnings estimates by 7 cents and revenue expectations by $240 million. Warning! GuruFocus has detected 4 Warning Sign with TGT.